meta
|
evidence
oncology
Living systematic review and meta-analysis
NSCLC neoadjuvant setting
1
lung cancer : small cell (SCLC)
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
Statistically conclusive or suggested result
Inconclusive results
Uncertain results
Safety results
NSCLC neoadjuvant setting
NSCLC neoadjuvant setting
versus placebo plus SoC
nivolumab plus SoC vs. placebo plus SoC
1
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open